Navigation Links
Questcor Reports 2010 Financial Results
Date:2/23/2011

ANAHEIM, Calif., Feb. 23, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today reported financial results for the full year and fourth quarter ended December 31, 2010.

For the year ended December 31, 2010, net sales increased 30.4 percent to a record $115.1 million from $88.3 million in the prior year.  The Company's financial performance was driven by an increase in net sales for H.P. Acthar® Gel (Acthar), for the treatment of acute exacerbations of multiple sclerosis (MS).  Full year 2010 net income was $35.1 million, or $0.54 per diluted common share.  Net income for 2009 was $26.6 million, or $0.40 per diluted common share.

"Strong gains in MS prescriptions throughout 2010 drove record net sales for Acthar and Questcor," said Don M. Bailey, President and CEO of Questcor. "Our number one focus in 2010, as it will be again in 2011, was the growth of MS prescriptions for Acthar.  In the fourth quarter, we expanded our MS sales force for the fourth time. Each of the previous expansions resulted in significantly increased sales.  We expect MS sales to continue to grow in 2011."

"Also in the fourth quarter, the FDA approved our sNDA for infantile spasms (IS) and modernized the label for Acthar, so that the label now includes 19 approved indications. This development allowed us to begin promotion of Acthar in IS as well as for the on-label indications associated with nephrotic syndrome (NS)," added Mr. Bailey.

"Despite the disruption caused by doubling our sales force, new shipped MS Acthar prescriptions so far in the first quarter of 2011 are running slightly ahead of the pace in the fourth quarter and well ahead of the pace in the first quarter of 2010," continued Mr. Bailey.  "Also in the first quarter we are initiating an in-depth commercial exploration of the on-label opportunity for Acthar in NS.
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
2. Questcor Pharmaceuticals Reports Strong Finish to 2010
3. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011
4. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Questcor to Present at the Maxim Group Growth Conference
6. Questcor Reports Third Quarter 2010 Results
7. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
8. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
9. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
10. Questcor to Present at UBS Global Life Sciences Conference
11. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Mass. , July 27, 2015 ... of Merck KGaA of Darmstadt, ... with celares GmbH to provide pegylation services to ... service offering enabled by the collaboration includes feasibility ... milligram to gram quantities required for pilot and ...
(Date:7/27/2015)... , July 27, 2015  Endo International plc (NASDAQ: ... 2015 financial results before the open of the U.S. financial ... management team will host a conference call and webcast at ... number to access the call is U.S./ Canada ... is 93183256. Please dial in 10 minutes prior to the ...
(Date:7/27/2015)... PITTSBURGH , July 27, 2015  Mylan N.V. ... regarding Teva,s (NYSE and TASE: TEVA) announcement of its ... and its withdrawal of its unsolicited expression of interest ... Robert J. Coury stated: "We congratulate Teva on ... their continued, and potentially enhanced, commitment to the generics ...
Breaking Medicine Technology:EMD Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH 2EMD Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH 3Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 2Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 3Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 4Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 5Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 6Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 7Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 8Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 9
... Safety Profile of the Intramuscular Formulation,of Peramivir ... BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ --,BioCryst ... I,clinical studies of an intramuscular (i.m.) formulation ... of Influenza Conference in,Toronto, Ontario, Canada. This ...
... 70 abstracts highlight VELCADE efficacy in broad range,of ... Mass., June 19, 2007 /PRNewswire-FirstCall/ --,Millennium Pharmaceuticals, Inc. ... therapy with unsurpassed single-agent,efficacy for patients with previously ... upcoming International Myeloma,Workshop (IMW) in Kos, Greece, June ...
Cached Medicine Technology:BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 2BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 3BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 4BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 5BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8
(Date:7/27/2015)... ... ... Dr. Robert G. Schwartz , principal of Greenville, SC-based Piedmont Physical ... Centers in order to offer his patients a new system of care utilizing laser ... , Peripheral neuropathy is a disease caused by damage to the peripheral nerves, and ...
(Date:7/27/2015)... ... 28, 2015 , ... Conducting Advanced Root Cause Analysis CAPA ... Quality of Investigations , **Presented by FDAnews and Learning Plus**, Sept. 16-17, 2015 ... the #1 reason for 483 observations since 1997! , The FDA's enforcement plan ...
(Date:7/27/2015)... ... ... The National Association of Professional Women (NAPW) honors Deana ... Circle. She is recognized with this prestigious distinction for leadership in healthcare. With more ... networking organization exclusively for professional women. , “I’m pleased to recognize Deana with this ...
(Date:7/27/2015)... ... July 28, 2015 , ... ... Baum- Lappe as a 2015 Professional Woman of the Year. Ms. Baum-Lappe ... most-recognized networking organization of professional women in the country, spanning virtually every industry ...
(Date:7/27/2015)... Falls Church, VA (PRWEB) , ... July 27, ... ... Quality and Compliance From Step One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 ... operating procedures are one of the first things FDA investigators will look at ...
Breaking Medicine News(10 mins):Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 3Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 4Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2Health News:NAPW Inducts Gilda Baum-Lappe, Journalist / Correspondent of Hollywood Foreign Press Association Into its VIP Woman of the Year Circle 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4
... A new organization, the American Society of Medical Doctors ... on issues that affect their relationship with patients. The first ... the organization will fight proposals for a government-run health care ... , "If these proposals are enacted, the American health ...
... of the International Diabetes Federation (IDF) is now open. ... 18-22, 2009 at Palais des Congrs de Montral (Montral ... world,s largest medical conferences, the 20th World Diabetes Congress ... level speakers and more than 200 national diabetes associations ...
... For more than 30 years, consumers have benefited from the ... effects of the sun, including sun burn, premature skin aging, ... efficacy of sunscreen products have been thoroughly studied and tested ... is an extensive body of credible scientific research that demonstrates ...
... the negative effect, study finds , THURSDAY, July 2 (HealthDay ... of early death, says a new study that challenges findings ... on nearly 44,000 men found that other major factors -- ... social circumstances as an adult -- nullify the effect of ...
... Six Ways to Chill Out This Summer , , SAN FRANCISCO, ... in the form of Metromint ( www.metromint.com ), the all-natural ... cooling sensation in every sip and is the perfect refreshment to beat ... tips for staying hydrated during the hot summer months: , , ...
... Genetics, Inc. (NYSE Amex: ILI ) announced today that ... Alan James Group assets of its subsidiary AJG Brands, Inc. to ... million in cash. The transaction was completed following the close of ... Alan James Group business saw an increase in sales during the ...
Cached Medicine News:Health News:American Society of Medical Doctors Established to Protect the Bond Between Physicians and Patients; Organizing Doctors to Oppose Government-Run Health Care 2Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 2Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 3Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 4Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 5Health News:Study Casts Doubt on Low IQ's Role in Early Death 2Health News:Nationwide Heat Wave Finally Gives Way To Cooling Trend 2Health News:Nationwide Heat Wave Finally Gives Way To Cooling Trend 3Health News:Interleukin Genetics Announces Strategic Divestment of Alan James Group 2
... camera system for high resolution photomicrography. The ... of the highest color fidelity, resolution and ... expect perfect images due to many unique ... innovative readout modes. The Leica DFC480 is ...
This compact photomicrographic system assures simple operation to achieve the exposure accuracy required for sophisticated photomicrography in most research and clinical environments....
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Stat Stain is ideal for stat, routine ... blood smears (10-15 seconds) and bone marrow ... finely dispersed stain particles which yield excellent ... many of the steps involved in the ...
Medicine Products: